📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 21:37
10 analysed today
10
Today
133,648
All-time analysed
40,136
Positive
6,284
Negative
79,406
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
₹189.2 Cr Stake Buy: Jubilant Ingrevia to Acquire 40% in Zettaone Technologies
Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd. for approximately ₹189.2 crore in cash. Zettaone is an electronics design and manufacturing platform (EDMS) with FY26 turnover of ₹98.1 crore (growing from ₹51.1 crore in FY24). The transaction will be completed in two tranches—tranche 1 by November 2026 and tranche 2 by September 2027—making Zettaone an associate company. This investment aligns with Jubilant Ingrevia's 'Pinnacle' strategy to build an integrated value chain across electronics and semiconductor spaces.
Confidence: HIGH
What changedJubilant Ingrevia approved acquiring a 40% strategic stake in EDMS platform Zettaone Technologies for ₹189.2 crore.
Why it mattersEnables the specialty chemical and CDMO player to expand into electronics and semiconductor manufacturing services, capturing higher-value deep-tech supply chains.
Acquisition Cost: ₹189.2 CrStake Acquired: 40%Target FY26 Turnover: ₹98.1 CrTarget FY25 Turnover: ₹79.1 CrCost vs Net Worth: ~7.2%Tranche 1 Completion: November 2026
📅 Short termPositive sentiment as the company takes a concrete step toward expanding its high-margin semiconductor and EDMS footprint without straining its balance sheet.
📈 Long termEnhances long-term capability to provide integrated high-tech hardware, PCB design, and semiconductor chemical solutions, supporting the company's Pinnacle growth roadmap.
⚠ Risk flags
- Integration risk and business model alignment between chemical CDMO and electronics hardware design
- Two-tranche closing timeline extends execution out to September 2027
Key Highlights
Acquisition of 40% strategic equity stake in Zettaone Technologies for ₹189.2 crore in cash
Target entity generated FY26 turnover of ₹98.1 crore, up from ₹79.1 crore in FY25 and ₹51.1 crore in FY24
Two-tranche completion schedule: Tranche 1 by November 2026 and Tranche 2 by September 2027
Transaction represents ~7.2% of Jubilant Ingrevia's net worth (₹2,640 crore) and ~1.6% of its market cap
👀 What to Watch
Track the closure of Tranche 1 by November 2026 and monitor synergy disclosures regarding CDMO cross-selling into semiconductor and electronics sectors in upcoming earnings calls.
Jubilant Ingrevia to Acquire 40% Stake in Zettaone for ₹189.2 Cr
Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited for approximately ₹189.2 crore in cash. The acquisition will be completed in two tranches, with the first closing expected by November 2026 and the second by September 2027, making Zettaone an associate company. Zettaone operates in electronics design and manufacturing (EDMS), posting revenue of ₹98.1 crore in FY26, up from ₹79.1 crore in FY25 and ₹51.1 crore in FY24. This transaction advances Jubilant's 'Pinnacle' strategy into the semiconductor and electronics value chain.
Confidence: HIGH
What changedJubilant Ingrevia approved a binding term sheet to acquire a 40% associate stake in deep-tech EDMS provider Zettaone Technologies for ₹189.2 crore.
Why it mattersEnables forward integration into the electronics and semiconductor hardware ecosystem, complementing the company's existing semiconductor chemical CDMO initiatives under its Pinnacle growth strategy.
Acquisition cost: ₹ 189.2 Cr.Stake acquired: 40%Target FY26 turnover: ₹ 98.1 Cr.Tranche 1 completion date: November 2026Tranche 2 completion date: September 2027Deal size vs Net Worth: ~7.2%
📅 Short termProvides positive strategic momentum; investors will track execution of definitive agreements and the Tranche 1 closure in November 2026.
📈 Long termPositioned to create synergies across semiconductor chemicals and high-speed PCB/electronics design for aerospace, defence, and automotive sectors over FY27–FY28.
⚠ Risk flags
- Two-stage acquisition timeline extending until September 2027 carries execution and integration timing risks.
- Target valuation (~4.8x FY26 sales) requires sustained high revenue growth and operating margin expansion.
Key Highlights
Acquiring a 40% strategic equity stake in Zettaone Technologies for an aggregate cash consideration of ₹189.2 crore.
Target company revenue grew 92% over two years, from ₹51.1 crore in FY24 to ₹79.1 crore in FY25 and ₹98.1 crore in FY26.
Two-tranche closing schedule: Tranche 1 by November 2026 and Tranche 2 by September 2027.
Deal value of ₹189.2 crore represents ~7.2% of Jubilant Ingrevia's net worth (₹2,640 crore) and ~4.1% of TTM revenue (₹4,651 crore).
👀 What to Watch
Monitor the definitive agreement signing and closing of Tranche 1 by November 2026, alongside management commentary on synergistic customer cross-selling between CDMO chemicals and EDMS.
Jubilant Ingrevia Q1 FY27: Rs 1,300 Cr Revenue Hits 15-Quarter High; EBITDA Up 36% YoY
Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to Rs 1,300 crore, a 15-quarter high. EBITDA increased 36% YoY to Rs 209 crore, driven by a massive 240% surge in the Chemical Intermediates segment and steady 26% margins in Specialty Chemicals. The company confirmed its 'Pinnacle 345' growth strategy, supported by a $300M+ 5-year CDMO contract with take-or-pay protection and a pipeline of 100+ molecules with Rs 3,500+ crore peak revenue potential. Management expects sequential improvements throughout the year as new capacities like the Gajraula MPP commission by late 2026.
Confidence: HIGH
What changedThe company has moved from a period of margin compression to a volume-led recovery across all segments, particularly in Chemical Intermediates and Nutrition.
Why it mattersThe strong performance validates the company's transition toward high-margin Specialty Chemicals and CDMO services, reducing its historical dependence on cyclical commodity chemicals.
Q1 Revenue: Rs 1,300 crQ1 Revenue vs TTM Revenue: ~29.6%YoY EBITDA Growth: 36%CDMO Peak Revenue Potential: Rs 3,500+ crSpecialty Chemicals EBITDA Margin: 26%Large CDMO Contract Value: $300M+
📅 Short termThe stock may see positive sentiment following the 15-quarter high revenue and significant EBITDA recovery in the intermediates segment.
📈 Long termThe 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over 5 years is supported by a strong CDMO funnel and upcoming high-tech semiconductor chemical facilities.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Pricing pressure in Pyridine and Picolines
- Geopolitical disruptions in the Middle East affecting supply chains
- Cyclicality in the Acetyls portfolio
Key Highlights
Revenue reached Rs 1,300 crore, representing 25% YoY growth and a 15-quarter high.
Chemical Intermediates EBITDA surged 240% YoY to Rs 57 crore due to robust demand and price escalations.
CDMO pipeline expanded to 100+ molecules with a peak revenue potential of Rs 3,500+ crore.
Confirmed $300M+ 5-year CDMO contract includes full take-or-pay protection for the company.
New Multi-Purpose Plant (MPP) at Gajraula remains on track for commissioning by the end of calendar year 2026.
👀 What to Watch
Monitor the execution timeline of the Gajraula MPP and the Bharuch CDMO Agro plant, as these are critical to fulfilling the $300M+ contract and achieving the 'Pinnacle 345' revenue targets.
41% PAT Growth: Jubilant Ingrevia Reports 15-Quarter High Revenue of ₹1,300 Cr in Q1 FY27
Jubilant Ingrevia delivered a strong Q1 FY27 with revenue growing 25% YoY to ₹1,300 crore, driven by robust demand in Chemical Intermediates and Nutrition segments. PAT surged 41% YoY to ₹106 crore, while EBITDA margins expanded to 16% from 15% in the previous year. The company reported a significant recovery in Chemical Intermediates EBITDA, which grew 240% YoY to ₹57 crore. Management highlighted a robust CDMO/Fine Chemicals pipeline of 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
Confidence: HIGH
What changedThe company has transitioned from a period of margin pressure to strong growth, achieving its highest revenue in nearly four years and significant margin recovery in the Intermediates segment.
Why it mattersThe results validate the company's diversified business model and its ability to pass through input costs, while the expanding CDMO pipeline provides long-term revenue visibility beyond cyclical chemical products.
Q1 FY27 Revenue: ₹1,300 CrRevenue vs TTM Revenue: 29.6%PAT Growth (YoY): 41%EBITDA Margin: 16%Pipeline Peak Revenue Potential: ₹3,500+ CrFY27 Lean Savings Target: ₹100 Cr
📅 Short termThe stock is likely to react positively to the 15-quarter high revenue and the sharp 240% YoY jump in Chemical Intermediates EBITDA.
📈 Long termThe 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over 5 years remains the structural driver, supported by entry into high-tech semiconductor chemicals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Pricing pressure in Pyridine
- Geopolitical disruptions in the Middle East affecting supply chains
- Cyclicality in the Acetyls portfolio
Key Highlights
Revenue reached a 15-quarter high of ₹1,300 crore, up 25% YoY and 10% QoQ.
PAT increased 41% YoY to ₹106 crore, with EPS rising to ₹6.7 from ₹4.7 in Q1 FY26.
Chemical Intermediates segment revenue grew 38% YoY to ₹524 crore with EBITDA margins jumping from 4% to 11%.
CDMO/Fine Chemicals pipeline stands at 100+ molecules with ₹3,500+ crore peak revenue potential.
Targeting ₹100 crore in annualized lean cost savings for FY27.
👀 What to Watch
Watch for the commissioning of the new Multi-Purpose Plant (MPP) by late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' growth strategy.
41% PAT Growth: Jubilant Ingrevia Reports Strong Q1 FY27 with ₹1,300 Cr Revenue
Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to ₹1,300 crore, marking a 15-quarter high. Net profit surged 41% YoY to ₹106 crore, driven by a significant rebound in the Chemical Intermediates segment where EBITDA grew 240% YoY. EBITDA margins improved to 16% from 15% a year ago, supported by cost pass-through and a richer product mix in CDMO and Fine Chemicals. The company maintains a robust CDMO pipeline of 100+ molecules with a peak revenue potential of ₹3,500+ crore.
Confidence: HIGH
What changedThe company has moved past the pricing pressures of previous quarters, achieving double-digit growth across all three business segments simultaneously.
Why it mattersThe results validate the company's shift toward high-margin Specialty Chemicals and CDMO, with the Chemical Intermediates segment finally showing a strong margin recovery (11% vs 4% YoY).
Q1 Revenue: ₹1,300 CrQ1 PAT: ₹106 CrRevenue vs TTM Revenue: 29.6%CDMO Peak Revenue Potential: ₹3,500+ CrEBITDA Margin: 16%
📅 Short termThe stock is likely to react positively to the 41% PAT growth and the 15-quarter high revenue, reflecting improved operational efficiency.
📈 Long termStructural growth is supported by the ₹3,500 Cr CDMO pipeline and entry into high-tech semiconductor chemicals, which could significantly re-rate the business as these projects commercialize.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geopolitical disruptions in the Middle East affecting supply chains
- Pricing pressure in the Pyridine portfolio
- Execution risk on the large-scale CDMO contract
Key Highlights
Revenue reached a 15-quarter high of ₹1,300 crore, representing 25% YoY and 10% QoQ growth.
PAT increased by 41% YoY to ₹106 crore, with EPS rising to ₹6.7 from ₹4.7 in Q1 FY26.
Chemical Intermediates EBITDA surged 240% YoY to ₹57 crore due to robust demand and price escalations.
CDMO pipeline includes 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
Nutrition segment EBITDA reached a 3-year high of ₹36 crore, up 45% YoY with 15% margins.
👀 What to Watch
Monitor the commissioning of the new Multi-Purpose Plant (MPP) scheduled for late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' strategy.
Rs 1,300 Cr Revenue: Jubilant Ingrevia Reports Strong Q1 FY27 with 44% YoY EPS Growth
Jubilant Ingrevia reported a strong start to FY27 with Q1 revenue from operations at Rs 1,300.27 Cr, representing approximately 29.6% of its TTM revenue. Profitability showed a healthy trend with EPS rising to Rs 5.83 from Rs 4.05 in the same quarter last year. Net profit margins expanded to 5.83%, up from 4.05% YoY and 5.08% QoQ. The company maintained a stable debt-to-equity ratio of 0.23 while granting 3,53,569 stock options to employees.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a significant step-up in both revenue and profitability compared to the previous four quarters.
Why it mattersThe margin expansion and revenue growth suggest successful execution in the Specialty Chemicals and CDMO segments, which are higher-margin areas compared to the company's traditional chemical intermediates.
Revenue (Q1 FY27): Rs 1,300.27 CrEPS (Q1 FY27): Rs 5.83Net Profit Margin: 5.83%Revenue vs TTM Revenue: ~29.6%Debt-to-Equity Ratio: 0.23
📅 Short termThe stock may react positively in the short term due to the notable YoY and QoQ improvement in margins and earnings per share.
📈 Long termThe company is structurally shifting towards a higher-margin profile through its CDMO contracts and semiconductor chemical entry, supporting its long-term goal to triple revenue in 5 years.
⚠ Risk flags
- Pricing volatility in Pyridine and Picolines
- Potential cost impact from the implementation of New Labour Codes
- Cyclicality in the Acetyls portfolio
Key Highlights
Revenue from operations reached Rs 1,300.27 Cr, a 26.9% increase over the Rs 1,024.34 Cr reported in June 2025
EPS grew 43.9% YoY to Rs 5.83 from Rs 4.05 in the corresponding previous year quarter
Net profit margin improved to 5.83% from 4.05% YoY and 5.08% in the preceding March 2026 quarter
Debt-to-equity ratio remains conservative at 0.23 as of June 30, 2026
Granted 3,53,569 stock options to eligible employees during the quarter
👀 What to Watch
Monitor the execution of the 'Pinnacle 345' plan and the commissioning of the new Multi-Purpose Plant (MPP) in Gajraula expected by late 2026, which are key to sustaining this growth momentum.
Jubilant Ingrevia Q1 Revenue up 25% YoY to Rs 1,300 Cr; Net Profit Margin expands to 5.83%
Jubilant Ingrevia reported a strong start to FY27 with consolidated revenue from operations reaching Rs 1,300.27 Cr, a 25.3% increase over the same quarter last year. Profitability showed significant improvement as net profit margins expanded to 5.83% from 4.05% in Q1 FY26. The company's balance sheet remains robust with a net worth of Rs 2,770.67 Cr and a conservative debt-to-equity ratio of 0.23. This performance reflects the company's progress toward its 'Pinnacle 345' strategy, supported by volume growth and cost-saving initiatives.
Confidence: HIGH
What changedThe company has demonstrated a significant YoY recovery in both top-line growth and profit margins, moving past the pricing pressures seen in previous quarters.
Why it mattersThe margin expansion indicates that the shift toward high-value Specialty Chemicals and CDMO services is beginning to offset cyclicality in the basic chemical intermediates segment.
Revenue (Q1 FY27): Rs 1,300.27 CrRevenue vs TTM Revenue: 29.6%Net Profit Margin: 5.83%Net Worth: Rs 2,770.67 CrDebt/Equity Ratio: 0.23
📅 Short termThe stock may see positive momentum in the coming weeks as the market reacts to the 25% YoY revenue growth and margin improvement.
📈 Long termThe structural growth story remains intact, driven by the 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over five years through high-tech chemical entries.
⚠ Risk flags
- Pricing volatility in Pyridine and Picolines
- Geopolitical risks affecting international trade (47% export share)
- Execution risk of large-scale CDMO contracts
Key Highlights
Consolidated revenue from operations grew 25.3% YoY to Rs 1,300.27 Cr compared to Rs 1,037.95 Cr in Q1 FY26.
Net profit margin improved to 5.83% from 4.05% in the corresponding quarter of the previous year.
Net worth increased to Rs 2,770.67 Cr as of June 30, 2026, up from Rs 2,640.06 Cr in March 2026.
Debt-to-equity ratio remains healthy at 0.23, slightly up from 0.20 in the previous quarter.
The company granted 3,33,569 stock options to eligible employees during the quarter.
👀 What to Watch
Investors should monitor the execution of the USD 300M+ CDMO contract starting in 2026 and the commissioning of the new Multi-Purpose Plant in Gajraula expected by late 2026.
Jubilant Ingrevia Reports Highest Q4 Revenue in 14 Quarters; EBITDA Up 11% YoY to ₹172 Cr
Jubilant Ingrevia reported a strong Q4 FY26 with revenue reaching ₹1,179 crore, a 12% YoY increase, and PAT rising 17% to ₹86 crore. The Specialty Chemicals segment achieved record quarterly revenue of ₹516 crore with stable 27% margins, while the Nutrition segment saw a 21% YoY revenue jump. Management highlighted the successful acquisition of Remidex Pharma and a robust CDMO pipeline of 100+ opportunities with a ₹3,500 crore potential. The company's leverage improved significantly, with Net Debt/EBITDA dropping to 0.99x.
Key Highlights
Q4 FY26 revenue grew 12% YoY to ₹1,179 crore, the highest in 14 quarters.
EBITDA for the quarter stood at ₹172 crore, up 11% YoY and 26% QoQ.
Specialty Chemicals segment maintained a 27% EBITDA margin for the sixth consecutive quarter.
Net Debt/EBITDA ratio improved to 0.99x, with net debt reducing by 11% in FY26.
CDMO pipeline includes 100+ opportunities with a total potential of ₹3,500 crore.
👀 What to Watch
Investors should monitor the ramp-up of the CDMO business and the integration of Remidex Pharma, as management expects sequential growth to continue into FY27. The stock remains attractive due to improving margins and a strengthening balance sheet.
Jubilant Ingrevia Q4 FY26: Highest Revenue in 14 Quarters at ₹1,179 Cr; PAT up 17% YoY
Jubilant Ingrevia reported its highest quarterly revenue in 14 quarters at ₹1,179 crore, a 12% YoY increase, driven by 10% volume growth. Profit After Tax (PAT) rose 17% YoY to ₹86 crore, while EBITDA grew 11% YoY to ₹172 crore with a healthy net debt to EBITDA ratio of 0.99x. The company declared a total dividend of ₹5 per share for FY26 and highlighted a robust pipeline of 100+ opportunities with a potential value of ₹3,500 crore. Management expects sequential growth to continue into FY27, led by Specialty Chemicals and Nutrition segments.
Key Highlights
Q4 FY26 revenue reached ₹1,179 crore, the highest in 14 quarters, with 10% volume growth.
EBITDA for the quarter stood at ₹172 crore, up 26% sequentially, with Specialty Chemicals maintaining 27% margins.
Net debt reduced by 11% during FY26, resulting in a net debt to EBITDA ratio of 0.99x.
Announced a final dividend of ₹2.5 per share, bringing the total FY26 dividend to ₹5 per share.
Identified a pipeline of 100+ opportunities with a potential peak revenue of ₹3,500 crore.
👀 What to Watch
Investors should monitor the execution of the ₹3,500 crore opportunity pipeline and the ramp-up of the new Bharuch CDMO plant. The stock remains attractive due to improving portfolio mix and significant deleveraging.
Jubilant Ingrevia Q4 FY26 PAT Rises 17% YoY to ₹86 Cr; Total Dividend at ₹5 per Share
Jubilant Ingrevia reported a strong Q4 FY26 with revenue growing 12% YoY to ₹1,179 crore, marking its highest revenue in 14 quarters. Profit After Tax (PAT) increased 17% YoY to ₹86 crore, supported by a 10% volume growth and effective cost pass-through despite global supply chain disruptions. The Specialty Chemicals segment maintained robust margins of 27%, while the Nutrition business saw a 21% revenue jump. The company also improved its balance sheet, reducing net debt by 11% and achieving a healthy Net Debt/EBITDA ratio of 0.99x.
Key Highlights
Q4 FY26 Revenue reached ₹1,179 crore, a 12% YoY increase driven by 10% volume growth.
EBITDA for the quarter stood at ₹172 crore, up 11% YoY and 26% sequentially (QoQ).
Board recommended a final dividend of ₹2.50 per share, bringing the total FY26 dividend to ₹5 per share (500%).
Specialty Chemicals segment EBITDA grew 21% in FY26, now contributing 75% to the total company EBITDA.
Net Debt decreased by 11% in FY26, resulting in a significantly improved Net Debt/EBITDA ratio of 0.99x.
👀 What to Watch
Investors should note the strong volume recovery and margin stability in the Specialty Chemicals and CDMO segments as evidence of the 'Pinnacle' strategy's success. The reduction in debt and consistent dividend payout make it a compelling watch for long-term growth in the specialty chemicals space.
Jubilant Ingrevia Q4 FY26 PAT Jumps 17% YoY to ₹86 Cr; Final Dividend of ₹2.50 Declared
Jubilant Ingrevia reported a strong Q4 FY26 with revenue growing 12% YoY to ₹1,179 crore, marking its highest revenue in 14 quarters. The company's PAT rose 17% YoY to ₹86 crore, supported by a 10% volume growth and effective cost pass-through despite Middle East supply chain disruptions. The Specialty Chemicals segment remained a key driver with 27% EBITDA margins, while the Nutrition segment saw a robust 21% YoY revenue growth. Management has signaled a positive outlook for FY27, focusing on CDMO expansion and the integration of the Remidex Pharma acquisition.
Key Highlights
Q4 FY26 Revenue increased 12% YoY to ₹1,179 crore with EBITDA rising 11% YoY to ₹172 crore.
Specialty Chemicals segment reported FY26 EBITDA growth of 21% with margins holding steady at 27%.
Net Debt/EBITDA improved to 0.99x as net debt was reduced by 11% during the financial year.
Board recommended a final dividend of ₹2.50 per share, bringing the total FY26 dividend to ₹5 per share.
Successfully commissioned the Bharuch CDMO plant and completed the acquisition of Remidex Pharma to boost Human Nutrition.
👀 What to Watch
Investors should take note of the consistent volume growth and the successful shift towards high-margin Specialty Chemicals and CDMO segments. The improving balance sheet and healthy dividend payout make it a strong candidate for long-term portfolios in the chemical space.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 Per Share for FY26
Jubilant Ingrevia Limited has announced a final dividend of Rs 2.50 per equity share, representing a 250% payout on its Re 1 face value for the financial year ended March 31, 2026. The company has established July 24, 2026, as the record date for determining eligibility, with the payout expected within 30 days of the AGM. Alongside the dividend, the board confirmed the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 fiscal year. This move signals a stable financial outlook and a consistent shareholder reward policy.
Key Highlights
Recommended a final dividend of 250% amounting to Rs 2.50 per equity share of Re 1 face value
Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment
Re-appointed M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27
The dividend payout is subject to shareholder approval at the upcoming Annual General Meeting
👀 What to Watch
Investors seeking dividend income should ensure they hold the shares before the record date of July 24, 2026. The 250% dividend payout indicates a healthy cash flow position and management's commitment to returning value to shareholders.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 per Share
Jubilant Ingrevia Limited has recommended a final dividend of Rs 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the Board has approved the re-appointment of M/s J.K. Kabra & Co. as the Cost Auditors for the 2026-27 financial year. The dividend payment is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended final dividend of 250% amounting to Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility set for Friday, July 24, 2026
Re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for FY 2026-27
Dividend to be paid within 30 days from the date of the Annual General Meeting
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the record date of July 24, 2026. The re-appointment of auditors suggests stability in the company's internal financial controls.
Jubilant Ingrevia Recommends 250% Final Dividend; Sets Record Date for July 24, 2026
Jubilant Ingrevia's Board has recommended a final dividend of Rs. 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine eligibility for this payout. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of the meeting. Additionally, the company has re-appointed M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 financial year.
Key Highlights
Recommended final dividend of Rs. 2.50 per equity share of Re. 1 face value (250%)
Record date for dividend eligibility fixed as Friday, July 24, 2026
Dividend payment to be completed within 30 days from the date of the Annual General Meeting
Re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for FY 2026-27 approved
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which is typically one working day prior to the July 24 record date.
Jubilant Ingrevia Recommends Final Dividend of Rs 2.50 Per Share for FY 2025-26
Jubilant Ingrevia Limited has recommended a final dividend of Rs 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine eligibility for the dividend payout. The board also approved the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 fiscal year. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs 2.50 per equity share of face value Re 1 each (250%).
Fixed July 24, 2026, as the record date for the purpose of final dividend payment.
Dividend to be paid or dispatched within 30 days from the date of the Annual General Meeting.
Re-appointed M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of July 24, 2026. The dividend yield should be calculated against the current market price to assess its attractiveness relative to peers.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 Per Share for FY26
Jubilant Ingrevia's Board has recommended a final dividend of Rs 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the Board approved the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the upcoming fiscal year 2026-27. The dividend payment is contingent upon approval by shareholders at the Annual General Meeting.
Key Highlights
Recommended a final dividend of 250% or Rs 2.50 per equity share of Re 1 face value for FY 2025-26.
Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment.
Approved the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27.
The dividend will be paid or dispatched within 30 days from the date of the Annual General Meeting.
👀 What to Watch
Investors seeking dividend income should ensure they hold the stock before the record date of July 24, 2026. While the dividend is positive, investors should also analyze the full FY26 financial results to assess the company's growth trajectory.
Jubilant Ingrevia Completes 100% Acquisition of Remidex Pharma Private Limited
Jubilant Ingrevia Limited has successfully finalized the acquisition of a 100% equity stake in Remidex Pharma Private Limited. This transaction follows the initial Share Purchase Agreement announced on March 13, 2026. The acquisition was completed on March 30, 2026, effectively making Remidex a wholly-owned subsidiary of the company. This move aligns with the company's strategic growth objectives in the pharmaceutical and chemical ingredients space.
Key Highlights
Acquired 100% equity stake in Remidex Pharma Private Limited
Transaction completed on March 30, 2026, at 6:05 PM IST
Follows the initial disclosure and agreement dated March 13, 2026
Remidex Pharma is now a wholly-owned subsidiary of Jubilant Ingrevia
👀 What to Watch
Investors should view this as a positive step toward inorganic growth and monitor the integration's impact on consolidated margins. Watch for further details on synergy benefits in the next quarterly earnings call.
Jubilant Ingrevia President of Speciality Chemicals Ambrish Dixit Resigns Effective March 31
Mr. Ambrish Dixit, the President of the Speciality Chemicals division at Jubilant Ingrevia, has resigned from his position. His departure is scheduled for the close of business hours on March 31, 2026. The company stated the reason for his resignation is to pursue a better professional opportunity. As Speciality Chemicals is a significant business segment for the company, investors should monitor the transition and the appointment of a successor.
Key Highlights
Mr. Ambrish Dixit resigned as President of the Speciality Chemicals division on March 26, 2026.
The resignation will take effect from the close of business hours on March 31, 2026.
The official reason cited for the departure is the pursuit of a better opportunity.
The announcement was made in compliance with Regulation 30 of SEBI LODR Regulations.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding a replacement for the Speciality Chemicals leadership role. While management turnover is common, leadership stability in high-margin segments is key to maintaining operational momentum.
Jubilant Ingrevia Starts Commercial Production of Agro Intermediate at Bharuch Site
Jubilant Ingrevia's wholly-owned subsidiary, Jubilant Agro Sciences Limited, has officially commenced commercial production of an Agro Intermediate at its Bharuch facility. This production is part of a strategic CDMO contract with a leading global agrochemical company. The company confirmed that the dispatch of materials has already begun as of March 21, 2026. This development marks a significant milestone in the company's specialty chemicals and CDMO growth trajectory.
Key Highlights
Commencement of commercial production of Agro Intermediate at the Bharuch site on March 21, 2026
Production is linked to a specific CDMO contract with a leading global Agrochemical Company
Immediate dispatch of materials started on the same day as the announcement
Executed through wholly-owned subsidiary Jubilant Agro Sciences Limited
👀 What to Watch
Investors should monitor the upcoming quarterly results for the revenue contribution from this new production line. This development strengthens the company's position in the high-margin CDMO segment and validates its execution capabilities.
Jubilant Ingrevia to Acquire 100% Stake in Remidex Pharma for Rs 16.5 Crore
Jubilant Ingrevia Limited has entered into a Share Purchase Agreement to acquire a 100% stake in Remidex Pharma Private Limited for a cash consideration of Rs 16.5 crore. Remidex is a Bangalore-based manufacturer of micronutrient premixes and nutraceuticals with a turnover of Rs 24.27 crore in FY 2024-25. This acquisition is a strategic move to help Jubilant Ingrevia move forward in the value chain within the Human Nutrition space, leveraging its existing leadership in Vitamins B3 and B4. The deal is expected to be completed within 30 days, making Remidex a wholly-owned subsidiary.
Key Highlights
Acquisition of 100% equity stake in Remidex Pharma for a cash consideration of Rs 16.5 crore.
Remidex reported a turnover of Rs 24.27 crore for FY 2024-25, compared to Rs 31.15 crore in FY 2023-24.
Strategic integration to expand into the Human Nutrition premix market using existing Vitamin B3 and B4 production.
Target entity operates a high-grade manufacturing facility in Bangalore with WHO-GMP and FSSC certifications.
The acquisition is expected to be finalized within an indicative period of 30 days.
👀 What to Watch
Investors should monitor the integration of Remidex as it represents a strategic shift toward higher-margin value-added products in the nutrition segment. While the acquisition size is small relative to Jubilant's scale, it strengthens their competitive position in the nutraceutical supply chain.
